Dianthus Therapeutics to Present Phase 3 CAPTIVATE Trial Results for CIDP Treatment

Dianthus Therapeutics, Inc. announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for March 9, 2026 at 8:00 a.m. ET. The company is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases.

To access the live conference call by phone, participants must pre-register to receive the dial-in number and personal PIN. The live webcast may be accessed via the Investors section of the Dianthus Therapeutics website at https://investor.dianthustx.com/. A replay of the webcast will be available following the call.

Claseprubart has already generated strong placebo-controlled Phase II data in gMG, reinforcing its profile as a competitive complement-pathway therapy. The drug is viewed as a potentially best-in-class C1s inhibitor in a high-need autoimmune neurology indication. The upcoming interim responder analysis from the open-label Phase II CAPTIVATE trial in CIDP is viewed as a key value inflection point.

The company is also pursuing a multi-indication strategy for claseprubart. Pivotal MoMeNtum data for the drug in MMN is expected in 2026.

A prior conference call on September 7, 2025 announced results from the Phase 2 MaGic trial for claseprubart in gMG and saw a 20% price move. An effective S-3 shelf filed on January 28, 2026 allows Dianthus to issue up to $600,000,000 of various securities over time, primarily to fund clinical and corporate needs.

Dianthus Therapeutics is based in New York City and Waltham, Mass., and is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.